Nanopath has announced that it has been awarded two grants worth a total of $4 million in federal funding through the Small Business Innovation Research (SBIR) program.
The Cambridge, MA-based molecular diagnostics firm was awarded a $3 million grant from the U.S. National Institutes of Health (NIH) and a $1 million grant from the National Science Foundation (NSF) to support further research and development of the company's point-of-care diagnostic platform for pelvic and gynecologic infections.
The new SBIR grants bring Nanopath's total funding to $15 million. Nanopath will use the funds toward development of its platform, including the test consumables and readout instrument, as well as for analytical and clinical validation of the company's lead assay. Nanopath has already developed advanced prototypes of both its disposable test cartridge and readout instrument.
Additionally, the company is working with hospitals in New England to actively develop its pipeline of tests.
